106 related articles for article (PubMed ID: 14716729)
1. Designing a large prevention trial: statistical issues.
Kryscio RJ; Mendiondo MS; Schmitt FA; Markesbery WR
Stat Med; 2004 Jan; 23(2):285-96. PubMed ID: 14716729
[TBL] [Abstract][Full Text] [Related]
2. Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
Meinert CL; Breitner JC
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S7-S14. PubMed ID: 18632005
[TBL] [Abstract][Full Text] [Related]
3. Treatment possibilities of Alzheimer's disease.
Miklya I; Gaszner P
Neuropsychopharmacol Hung; 2004 Dec; 6(4):200-9. PubMed ID: 15825676
[TBL] [Abstract][Full Text] [Related]
4. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease.
Doody RS
Alzheimers Dement; 2009 Mar; 5(2):133-6. PubMed ID: 19328443
[TBL] [Abstract][Full Text] [Related]
5. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements.
Goodman GE; Thornquist MD; Balmes J; Cullen MR; Meyskens FL; Omenn GS; Valanis B; Williams JH
J Natl Cancer Inst; 2004 Dec; 96(23):1743-50. PubMed ID: 15572756
[TBL] [Abstract][Full Text] [Related]
6. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study.
Zandi PP; Sparks DL; Khachaturian AS; Tschanz J; Norton M; Steinberg M; Welsh-Bohmer KA; Breitner JC;
Arch Gen Psychiatry; 2005 Feb; 62(2):217-24. PubMed ID: 15699299
[TBL] [Abstract][Full Text] [Related]
7. Potential prevention strategies for Alzheimer disease.
Thal LJ
Alzheimer Dis Assoc Disord; 1996; 10 Suppl 1():6-8. PubMed ID: 8876780
[TBL] [Abstract][Full Text] [Related]
8. Vitamin C and vitamin E for Alzheimer's disease.
Boothby LA; Doering PL
Ann Pharmacother; 2005 Dec; 39(12):2073-80. PubMed ID: 16227450
[TBL] [Abstract][Full Text] [Related]
9. Burden of Alzheimer's disease: population-based estimates and projections for New Zealand, 2006-2031.
Tobias M; Yeh LC; Johnson E
Aust N Z J Psychiatry; 2008 Sep; 42(9):828-36. PubMed ID: 18696288
[TBL] [Abstract][Full Text] [Related]
10. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
[TBL] [Abstract][Full Text] [Related]
11. 2009 Alzheimer's disease facts and figures.
Alzheimer's Association
Alzheimers Dement; 2009 May; 5(3):234-70. PubMed ID: 19426951
[TBL] [Abstract][Full Text] [Related]
12. Methodology of an ongoing, randomized controlled trial to prevent falls through enhanced pharmaceutical care.
Ferreri S; Roth MT; Casteel C; Demby KB; Blalock SJ
Am J Geriatr Pharmacother; 2008 Jun; 6(2):61-81. PubMed ID: 18675765
[TBL] [Abstract][Full Text] [Related]
13. Alcohol intake and risk of dementia.
Luchsinger JA; Tang MX; Siddiqui M; Shea S; Mayeux R
J Am Geriatr Soc; 2004 Apr; 52(4):540-6. PubMed ID: 15066068
[TBL] [Abstract][Full Text] [Related]
14. Incidence and subtypes of dementia in three elderly populations of central Spain.
Bermejo-Pareja F; Benito-León J; Vega S; Medrano MJ; Román GC;
J Neurol Sci; 2008 Jan; 264(1-2):63-72. PubMed ID: 17727890
[TBL] [Abstract][Full Text] [Related]
15. What do people at risk for Alzheimer disease think about surrogate consent for research?
Kim SY; Kim HM; McCallum C; Tariot PN
Neurology; 2005 Nov; 65(9):1395-401. PubMed ID: 16275826
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study.
Khachaturian AS; Corcoran CD; Mayer LS; Zandi PP; Breitner JC;
Arch Gen Psychiatry; 2004 May; 61(5):518-24. PubMed ID: 15123497
[TBL] [Abstract][Full Text] [Related]
17. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
18. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
Brinton RD
Ann N Y Acad Sci; 2005 Jun; 1052():57-74. PubMed ID: 16024751
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
[TBL] [Abstract][Full Text] [Related]
20. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
